The U.S. Food and Drug Administration has granted approval to Empaveli as the primary treatment for C3 glomerulopathy .The drug has received approval for patients over 12 years and above who work to ...

The company's customer wins this year suggest more revenue expansion to come. In fact, C3.ai forecasts fiscal 2026 sales to ...

This has led to strong growth for the company, with C3.ai's revenue rising 25% year over year in fourth-quarter fiscal year 2025 (ending April 30). It also expects strong growth for FY 2026, with ...

Upgrade your portfolio! C3.ai is a strong buy with explosive growth, top-tier partnerships, and AI exposure at a discount.

This approval offers a promising new targeted treatment for patients aged 12 and older with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), ...

For three days inside the Charleston Convention Center, fire, EMS, law enforcement and dispatchers from the tri-county ...

BornHack is a week-long summer hacker camp in a forest on the Danish island of Fyn, that consistently delivers a very ...

Developer Howard Saffan and concert promoter Jim Koplik helped establish the music event in 2021 and are not ready to say ...

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the biotech stocks to buy according to Wall Street analysts.

Discover new safety insights on Syfovre for geographic atrophy treatment, as Roger A. Goldberg highlights promising long-term data at ASRS 2025.

As Lollapalooza returns to Chicago’s Grant Park this weekend, organizers are once again turning up the volume on ...

Airports across the UK are enforcing different 100ml liquid systems, threatening to cause hold-ups in security lanes as the ...